Recce topical gel shows strong diabetic foot infection efficacy ahead of Phase III data review

A review of blinded data from Recce Pharmaceuticals’ Phase III trial in Indonesia of RECCE 327 Gel (R327G) in diabetic foot infections (DFIs) by clinical experts and a…

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.couriermail.com.au)